{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=53", "query": { "condition": "Neuroendocrine Cancer", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 2745, "total_pages": 275, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=54&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=52&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T01:29:45.008Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03526185", "title": "A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Tumor Infiltrating Lymphocytes", "type": "DRUG" }, { "name": "Nivolumab and Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-02-06", "completion_date": "2020-12-01", "has_results": false, "last_update_posted_date": "2022-07-25", "last_synced_at": "2026-10-31T01:29:45.008Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03526185" }, { "nct_id": "NCT02978625", "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma, ALK-Negative", "Anaplastic Large Cell Lymphoma, ALK-Positive", "Apocrine Carcinoma", "Carcinoma Arising From Cylindroma", "Carcinoma Arising From Spiradenoma", "Digital Papillary Adenocarcinoma", "Endocrine Mucin-Producing Sweat Gland Carcinoma", "Extramammary Paget Disease", "Extraocular Sebaceous Carcinoma", "Hidradenocarcinoma", "Malignant Sweat Gland Neoplasm", "Merkel Cell Carcinoma", "Microcystic Adnexal Carcinoma", "NK-Cell Lymphoma, Unclassifiable", "Papillary Adenocarcinoma", "Porocarcinoma", "Primary Cutaneous Mucinous Carcinoma", "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory Anaplastic Large Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Merkel Cell Carcinoma", "Refractory Mycosis Fungoides", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Skin Squamous Cell Carcinoma", "Refractory T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome", "Signet Ring Cell Adenocarcinoma", "Skin Adenoid Cystic Carcinoma", "Skin Adnexal Carcinoma", "Skin Basal Cell Carcinoma", "Skin Basosquamous Cell Carcinoma", "Skin Keratoacanthoma", "Skin Squamous Cell Carcinoma", "Squamoid Eccrine Ductal Carcinoma", "Squamous Cell Carcinoma of Unknown Primary", "Sweat Gland Carcinoma", "Trichilemmal Carcinoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Mammography", "type": "PROCEDURE" }, { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2017-09-27", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-31T01:29:45.008Z", "location_count": 36, "location_summary": "Los Angeles, California • Orange, California • Pasadena, California + 28 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02978625" }, { "nct_id": "NCT02752074", "title": "A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "pembrolizumab + epacadostat", "type": "DRUG" }, { "name": "pembrolizumab + placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 706, "start_date": "2016-06-21", "completion_date": "2019-08-16", "has_results": true, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-10-31T01:29:45.008Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02752074" }, { "nct_id": "NCT02974725", "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Melanoma" ], "interventions": [ { "name": "LXH254", "type": "DRUG" }, { "name": "LTT462", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2017-02-24", "completion_date": "2024-04-24", "has_results": false, "last_update_posted_date": "2025-04-13", "last_synced_at": "2026-10-31T01:29:45.008Z", "location_count": 6, "location_summary": "San Diego, California • San Francisco, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02974725" }, { "nct_id": "NCT07338968", "title": "A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Choroidal Melanoma", "Indeterminate Lesions" ], "interventions": [ { "name": "Observational", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Aura Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2026-03-27", "completion_date": "2033-08-15", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-31T01:29:45.008Z", "location_count": 10, "location_summary": "Sacramento, California • Ann Arbor, Michigan • Rochester, Minnesota + 7 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07338968" }, { "nct_id": "NCT05573035", "title": "A Study to Investigate LYL845 in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "LYL845", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lyell Immunopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 39, "start_date": "2022-12-19", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-10-31T01:29:45.008Z", "location_count": 18, "location_summary": "Sacramento, California • Santa Monica, California • Stanford, California + 14 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05573035" }, { "nct_id": "NCT04754425", "title": "Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Prostate Adenocarcinoma", "Metastatic Prostate Small Cell Neuroendocrine Carcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Erdafitinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 11, "start_date": "2021-07-15", "completion_date": "2026-02-02", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-31T01:29:45.008Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04754425" }, { "nct_id": "NCT01515189", "title": "Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 831, "start_date": "2012-02-17", "completion_date": "2017-08-17", "has_results": true, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-10-31T01:29:45.008Z", "location_count": 11, "location_summary": "Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01515189" }, { "nct_id": "NCT01123304", "title": "Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "MORAb028", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2010-05", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2014-07-17", "last_synced_at": "2026-10-31T01:29:45.008Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01123304" }, { "nct_id": "NCT06021626", "title": "A Study of CRD3874-SI in People With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "CRD3874", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2023-08-25", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-31T01:29:45.008Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06021626" } ] }